Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

CLL cells | Image Credit: © sovova - stock.adobe.com
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

June 30th 2025

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

After adjustment for imbalances, patients in the liso-cel group had an overall response rate of 52.5%, compared with 19.2% in the standard-of-care group. | Image credit: fotogurmespb- stock.adobe.com
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy

June 26th 2025

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Cytogenetic risk factors do not appear to affect survival outcomes following first-line ibrutinib for CLL/SLL, real-world survival data suggest. | Image credit: Saiful52 - stock.adobe.com
First-Line Ibrutinib Effective in CLL/SLL With or Without Risk Factors

June 13th 2025

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.  | Image credit: wladimir1804 - AdobeStock_408414612
FDA Approves Tablet Formulation of Zanubrutinib for All Indications

June 11th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo